Effects of 60-day-6° Head-down Bed Rest on Cartilage and Function of the Knee Joint
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Sep 24, 2024
Trial Information
Current as of November 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining how spending 60 days lying in a head-down position (like being in a zero-gravity environment) affects the knee joint's cartilage and overall function. Researchers want to understand how this type of bed rest, which simulates the feeling of weightlessness, impacts the quality of the cartilage in the knee. They will use advanced imaging technology to study these effects.
To participate in this trial, you need to be a male aged between 25 and 50, with a height of 160-175 cm and a weight of at least 50 kg. You should also have a healthy general condition. If you have a history of alcohol or drug issues, smoke heavily, or have certain health conditions like severe vertigo, you won't be eligible. If you join, you can expect to be part of a study that aims to help scientists learn more about how our bodies respond to prolonged bed rest, which can be important for understanding health in space travel and other situations where movement is limited.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • (1) male; (2) age 25-50 years old; (3) height between 160-175 cm, weight ≥50kg, and BMI between 18.5-26 kg/m²; (4) good general health status.
- Exclusion Criteria:
- • (1) history of alcoholism; (2) smoking ≥5 cigarettes/day in the 3 months before the test; (3) drug dependence or use of medications affecting bone metabolism within 2 weeks before screening; (4) presence of metal implants, severe vertigo, or severe snoring.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Beijing, Beijing, China
Patients applied
Trial Officials
Jianquan Wang, M.D.
Study Chair
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported